There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular
diseases. These factors have a significant impact on the decision to use one therapy
over another. The past decade has seen a paradigm shift in our understanding of the
pathogenesis of psoriasis that has led to identification of new therapeutic targets.
Several new drugs have gained approval by the US Food and Drug Administration, expanding
the psoriasis armamentarium, but still a large number of patients continue to be untreated
or undertreated. Treatment regimens for psoriasis patients should be tailored to meet
the specific needs based on disease severity, the impact on quality of life, the response
to previous therapies, and the presence of comorbidities. The first article in this
continuing medical education series focuses on specific comorbidities and provides
insights to choose appropriate systemic treatment in patients with moderate to severe
psoriasis.